Latest stories on AUPH
Aurinia Posts Strong Q2 2026 Results on Rising LUPKYNIS Sales
TipRanks67 · bullishearnings
Aurinia Posts Strong Q2 Results, Reaffirms 2026 Outlook and Advances Autoimmune Pipeline
TipRanks68 · bullishearnings
Aurinia Pharmaceuticals Reports 74% Net Income Growth and Initiates New Lupus Nephritis Study—Is the Pace Sustainable?
August 6, 2026
MarketChameleon73 · bullishproduct/pr
Aurinia Pharmaceuticals Inc. (AUPH) files 8-K
SEC 8-K50 · neutralgeneral
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
Yahoo Top57 · neutralanalyst
Aurinia Pharmaceuticals and Four More Stocks See Activist Action
Barron's55 · neutralgeneral
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
TipRanks56 · neutralproduct/pr
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
The Motley Fool63 · neutralgeneral
Tang Capital Boosts Stake in Aurinia Pharmaceuticals—Owns 10% After $3.1 Million Stock Purchase
MarketChameleon63 · neutralgeneral
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
Seeking Alpha73 · bullishproduct/pr
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death | AUPH Stock News
StockTitan73 · bullishproduct/pr
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha50 · neutralgeneral
Tang Capital takes 10% stake in Aurinia Pharma
Seeking Alpha56 · neutralgeneral